Dr. Israel was able to share her experience in value framework in oncology with the bladder cancer community. The idea behind value framework from ASCO is focus to support informed, shared decision making between doctor and patient. Its goal is to develop and employ a tool that can customize information for each patient, and to remind the physician that the primary responsibility is the patient.
Elements considered when developing framework are: clinical benefit, toxicity, cost, universal access, lost wages and patient satisfaction. Their framework includes a primary focus on overall survival, then progression free survival and lastly recurrence free survival, in decreasing order, with a focus on extended survival off therapy. It considers toxicity with symptom palliation and quality of life, and lastly cost to the patient and system. His clinical benefit calculator will help quantify overall value in discussion with patients. Dr. Schnipper discusses other Frameworks, the ESMO, NCCN evidence blocks, ICER, and Drug Abacus. Each have different parameters and scope. Threshold for value however, is to be determined and is patient and disease state specific.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Presented By: Lowell Schnipper, MD, Beth Israel Deaconess Medical Center
Written by: Michael J Metcalfe, MD. Fellow of Urologic Oncology Urology, MD Anderson Cancer Center, Houston TX
Ashish M. Kamat, MD, MBBS, FACS
President, International Bladder Cancer Network
Chair, Society of Immunotherapy for Cancer (SITC), BCTF
Director of Urologic Oncology Fellowship
Professor of Urology
Attending Surgeon, Division of Surgery
The University of Texas, MD Anderson Cancer Center